{"id":296884,"date":"2026-07-08T15:13:39","date_gmt":"2026-07-08T22:13:39","guid":{"rendered":"https:\/\/jthelander.com\/?p=296884"},"modified":"2026-07-08T15:13:39","modified_gmt":"2026-07-08T22:13:39","slug":"biotech-ceo-compensation-real-inflection-point","status":"publish","type":"post","link":"https:\/\/brightturn.io\/?p=296884","title":{"rendered":"Biotech CEO Compensation: The Real Inflection Point"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">The real inflection point in biotech CEO compensation isn&#8217;t between early and late clinical trials. It&#8217;s the leap from pre-clinical to clinical. In this data drop, pulled directly from the <a href=\"http:\/\/platform.jthelander.com\" target=\"_blank\" rel=\"noreferrer noopener\">Thelander Platform<\/a>, we looked at how median total cash, founder and non-founder equity changes across biotech stages of development.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Pre-Clinical \u2192 Clinical<\/strong><br>Median total cash: $329,067 \u2192 $447,500<br>Median total founder equity: 16.00% \u2192 9.00%<br>Median non-founder equity: Steady at 5.00%<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" src=\"https:\/\/jthelander.com\/wp-content\/uploads\/PC_Data_Drop_7-8_26_Chart-1-700x478.png\" alt=\"\" class=\"wp-image-296885\"\/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Clinical Phase I \u2192 Phase II\/III<\/strong><br>Median total cash: $452,500 \u2192 $445,720<br>Median total founder equity: 7.99% \u2192 9.90%<br>Median non-founder equity: 5.00% \u2192 4.74%<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" src=\"https:\/\/jthelander.com\/wp-content\/uploads\/PC_Data_Drop_7-8-27_Chart-2-700x488.png\" alt=\"\" class=\"wp-image-296886\"\/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>The takeaway?<\/strong> CEO total cash jumps significantly between the pre-clinical and clinical phases of biotech development, with a corresponding decrease in founder equity while non-founder equity stays steady. There is much less of a difference in CEO comp between the earlier and later clinical phases, suggesting the main difference is between pre-clinical and clinical.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The biotech stage of development filter is available on the Thelander Platform. To trial the platform for no charge and access customized real-time compensation data, fill out the <a href=\"http:\/\/survey.jthelander.com\" target=\"_blank\" rel=\"noreferrer noopener\">survey today<\/a>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The real inflection point in biotech CEO compensation isn&#8217;t between early and late clinical trials. It&#8217;s the leap from pre-clinical to clinical. In this data drop, pulled directly from the Thelander Platform, we looked at how median total cash, founder and non-founder equity changes across biotech stages of development. Pre-Clinical \u2192 ClinicalMedian total cash: $329,067 [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[4],"class_list":["post-296884","post","type-post","status-publish","format-standard","hentry","category-data-drops","tag-private-company"],"_links":{"self":[{"href":"https:\/\/brightturn.io\/index.php?rest_route=\/wp\/v2\/posts\/296884","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/brightturn.io\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/brightturn.io\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/brightturn.io\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/brightturn.io\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=296884"}],"version-history":[{"count":0,"href":"https:\/\/brightturn.io\/index.php?rest_route=\/wp\/v2\/posts\/296884\/revisions"}],"wp:attachment":[{"href":"https:\/\/brightturn.io\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=296884"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/brightturn.io\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=296884"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/brightturn.io\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=296884"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}